Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.
CRC
DRUG: HLX07|DRUG: HLX10|DRUG: mFOLFOX6
ORR, Objective response rate (assessed by investigator per RECIST V1.1), up to 3 years|PFS, Progression-free survival (PFS) (assessed by the investigator per RECIST v1.1 ), : from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier)ï¼Œup to 3 years
OS, Overall Survival, up to 5 years
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.